MyPeptideMatchOverview
CJC-1295 is a modified GHRH analog (modified GRF 1-29) that prolongs growth hormone release, making it attractive for sustained GH support. It has been marketed for anti-aging, muscle support, and recovery. CJC-1295 is prohibited for compounding in the US. Its Category 2 nomination was withdrawn in September 2024; there is no approved pathway. Importantly, the FDA has flagged CJC-1295 for heart-related (cardiac) side effects. Patients and providers should not assume it is safe or legal to use. Sermorelin is a legal, compoundable alternative for GH stimulation. Evidence for CJC-1295 is moderate—limited human studies—and the cardiac concerns add significant risk.
How It Works (Mechanism of Action)
CJC-1295 is a long-acting GHRH analog that stimulates the pituitary to release GH over an extended period. The modification increases half-life compared with native GHRH or sermorelin.
Primary Uses
Marketed for sustained GH release, anti-aging, and muscle support. Evidence moderate. Not legal for compounding. Cardiac risks flagged by FDA.
